Developer docs
API playgroundTry for free, no card

Search company profiles

MILabs

Full company profile

uuid000fhbi

Namestring
MILabs
Legal namestring
MILabs B.V.
Websiteurl
milabs.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

MILabs B.V., headquartered in Houten, Netherlands, is a privately held developer and manufacturer of ultra-high resolution preclinical and clinical molecular imaging systems. Founded in 2006 as a spin-off from the University Medical Centre Utrecht by Professor Frederik Beekman, the company designs integrated platforms combining SPECT, PET, CT, and Optical imaging modalities on a single scalable workflow. Its core proprietary technologies include clustered multi-pinhole collimators optimized for up to 511 keV photon energies, the VECTor platform (the world's first true simultaneous in vivo SPECT and PET system with sub-millimeter resolution), Confocal/Spectral PET for multi-isotope imaging, and the Super Cluster Collimator for theranostic radionuclides such as Ac-225 and At-211. MILabs also offers the G-SPECT clinical system for human imaging, extending its technology base into diagnostic clinical applications.

The company sells high-value capital equipment primarily to academic research institutions (e.g., Beckman Institute, Mayo Clinic, Duke, Purdue, UPENN, VUB) and pharmaceutical/biotechnology firms, with secondary demand from nuclear medicine departments and CROs. Revenue is generated through hardware sales, system upgrades and accessories, professional service and support contracts, and licensing of patented imaging technologies, all conducted via a quote-based sales process. Distribution combines direct enterprise sales with regional channel partners (e.g., HongKong Meilin Group in China, Mid-Atlantic Imaging Services in the Americas) and co-development relationships (TU Delft, SkyScan, UPENN, RS2D). Since August 2021, MILabs has operated as a subsidiary of Rigaku Group (Tokyo, Japan), continuing to develop advanced preclinical imaging systems under founder-led scientific leadership.

Short descriptiontext

MILabs B.V. designs and sells ultra-high-resolution preclinical and clinical molecular imaging systems (SPECT, PET, CT, Optical) based on proprietary multi-pinhole collimator technology, serving academic research institutions, pharmaceutical companies, and nuclear medicine departments worldwide as a subsidiary of Rigaku Group.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersHouten, Netherlands
HQ citystring
Houten
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical imaging, molecular imaging systems, SPECT imaging, PET imaging, micro-CT imaging
Industry3 codes
PRIMARYHLAHABAE
Nuclear Medicine & Molecular Imaging (SPECT/PET)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code3 codes
  • Laboratory Analytical Instruments3826
  • Electromedical & Electrotherapeutic Apparatus3845
  • X-Ray Apparatus & Tubes & Related Irradiation Apparatus3844
Product category
Preclinical Molecular Imaging Systems
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Preclinical Imaging Systems Sales
TypeHardware Sales
Description

MILabs generates primary revenue from selling high-end preclinical molecular imaging systems (SPECT, PET, CT, Optical) to research institutions and pharmaceutical companies. Systems are sold as integrated platforms with various modality configurations.

milabs.com
2System Upgrades and Accessories
TypeHardware Sales
Description

Revenue from upgrading existing systems with new collimators (e.g., VECTor upgrade for U-SPECT-II), accessories, and application-specific configurations.

milabs.com
3Service and Support
TypeProfessional Services
Description

Installation, training, application support, and ongoing service maintenance for installed systems through direct staff and regional service partners.

milabs.com
4Technology Licensing
TypeLicensing Royalties
Description

Licensing of proprietary imaging technologies and patented collimator designs.

milabs.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1Custom-configured preclinical imaging systems
ModelOtherBilling cadenceMulti-year contract
Notes

Systems are configured based on customer research needs, combining modalities (SPECT, PET, CT, Optical). Pricing varies by configuration, resolution requirements, and accessory packages. Quote-based sales process via website contact form.

milabs.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

MILabs designs, manufactures, and sells high-end preclinical and clinical molecular imaging systems for biomedical research. Its portfolio integrates SPECT, PET, CT, and Optical modalities on a single scalable platform, using patented multi-pinhole collimator technology to deliver sub-half-millimeter spatial resolution. Core offerings include U-SPECT, VECTor (simultaneous SPECT/PET), U-PET/CT, Optical imaging, integrated micro-CT, and the G-SPECT clinical system, with specialized collimators such as the Super Cluster Collimator for theranostic radionuclides.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 0.25mm spatial resolution achieved with U-SPECT technology
+4 more records
Product overview1 text field

MILabs is a preclinical and clinical molecular imaging company offering a comprehensive portfolio of imaging systems. The core product line includes U-SPECT (ultra-high resolution SPECT), VECTor (simultaneous SPECT/PET), U-PET (high-resolution PET with Spectral PET capability), and integrated CT systems. Products range from bench-top mini systems to fully integrated multi-modality platforms combining SPECT/PET/CT and MRI. The portfolio includes specialized collimators (Super Cluster Collimator for theranostics), and extends into clinical imaging with G-SPECT for human SPECT applications. MILabs was acquired by Rigaku Group in August 2021 and continues to develop advanced imaging technologies.

Product and service11 records
1VECTor/CT
CategoryPreclinical Molecular Imaging Systems
Description

Versatile Emission Computed Tomography system combining simultaneous SPECT and PET imaging with integrated CT for preclinical research; the world's first true simultaneous in vivo SPECT/PET preclinical imaging device delivering sub-mm resolution for both modalities.

2U-SPECT
CategoryPreclinical Molecular Imaging Systems
Description

Ultra-high resolution Single Photon Emission Computed Tomographer providing the highest resolution SPECT imaging available (down to 0.25mm isotropic uniformly over the field of view) with patented focused multi-pinhole cylindrical collimators for preclinical research.

3U-SPECT/CT
CategoryPreclinical Molecular Imaging Systems
Description

Integrated U-SPECT system combined with high-throughput, low-dose micro-CT for fusion of anatomical images with functional SPECT, ensuring high precision data analysis in preclinical research.

4U-CT
CategoryPreclinical Micro-CT Systems
Description

High-resolution micro-CT subsystem for anatomical imaging, available at multiple resolution levels with fast scan times and low-dose performance for molecular imaging applications.

5Optical Imaging
CategoryPreclinical Optical Imaging Systems
Description

Optical imaging module including 3D and 4D capabilities for molecular imaging applications. Available as standalone 2D optical imaging or hybrid Optical/CT imaging system with Duet Optical docking station.

6VECTor OI/CT
CategoryPreclinical Molecular Imaging Systems
Description

Hybrid Optical Imaging with in-line X-ray CT system featuring unique Duet Optical docking station for both high-throughput 2D optical imaging and CT-guided 3D optical tomography of deep tissue.

7U-PET/CT
CategoryPreclinical PET Imaging Systems
Description

High-resolution PET system with Confocal PET technology enabling Spectral PET (Color PET) for simultaneous detection of dual isotopes and significantly improved signal-to-noise contrast in preclinical research.

8Super Cluster Collimator (SC)
CategoryImaging Accessories and Collimators
Description

Accessory transforming challenging theranostic radionuclides into quantifiable preclinical insight. Provides ultra-high sensitivity (~17%) while maintaining spatial resolution of approximately 1.1-1.3mm at high gamma energies, enabling simultaneous multi-photopeak detection for Ac-225, At-211 and other low-signal isotopes.

9G-SPECT Clinical SPECT System
CategoryClinical Imaging Systems
Description

Clinical SPECT system for human use providing <3mm spatial resolution (compared to typical 8-10mm of existing clinical SPECT) with ultra-fast scanning and no rotating detectors. Designed for brain, kidneys and joint imaging with applications in epilepsy, Parkinson's, and Alzheimer's diagnosis.

10VECTor4 and U-SPECT4 Series
CategoryPreclinical Molecular Imaging Systems
Description

New 4-series product line comprising U-SPECT4, U-SPECT4CT, VECTor4 and VECTor4CT with significant improvements including more compact design, dramatically improved X-Ray CT subsystem with reduced radiation dose, increased resolution and speed.

11PET-SPECT-CT-MRI Platform
CategoryPreclinical Multi-Modality Imaging Platforms
Description

Comprehensive preclinical imaging platform combining PET, SPECT, CT and MRI modalities. Integrates sub-half-mm SPECT resolution, sub-mm PET resolution, with high-resolution X-ray CT and/or compact cryogen-free 1.5T MRI unit for nanobody and multimodal research.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1HongKong Meilin Group Co., Ltd.
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2015-01-27
Description

Local partner in China providing sales, technical, and marketing support for MILabs products in the Chinese market. HongKong Meilin Group is a professional distributor for biological research equipment covering molecular imaging, molecular biology, cytology, and immunology.

milabs.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2014-09-01
Description

Collaboration between UPENN Physics and Instrumentation Group, MILabs, and TU Delft for adaptive SPECT development. Dr. Scott Metzler's work focuses on high performance SPECT instrumentation and image reconstruction.

3Trace'nTreat Network (Marie Curie ITN)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2012-10-23
Description

MILabs participates in Trace'nTreat network, a Marie Curie Initial Training Network funded with over 2 million euros by the European Commission. Network trains young researchers in nuclear diagnostics and radionuclide therapy across academic and private partners including Erasmus MC, TU Delft, and others.

milabs.com
4SkyScan N.V.
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2011-01-11
Description

Strategic partnership with SkyScan N.V. (Kontich, Belgium) to deliver highest resolution CT systems integrated with MILabs U-SPECT and VECTor platforms. Partnership includes compatible animal holders, bed designs, and Click-Over interface software for automatic fusion of CT datasets with functional molecular imaging.

milabs.com
5Mid-Atlantic Imaging Services
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2010-12-09
Description

Strategic service and support agreement for US and Canada. Mid-Atlantic Imaging Services provides installation and first response service support to MILabs customers, supporting MILabs growth and expansion in the Americas market.

milabs.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2009-05-31
Description

Academic partnership with TU Delft for development of combined PET/SPECT imaging technology leading to VECTor product. Prof. Freek Beekman, founder of MILabs, is professor at TU Delft and previously led development of U-SPECT at the university. Joint research collaboration continues for SPECT protocol optimization and technology development.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Bruker's Molecular Imaging business offers preclinical PET, SPECT, CT, MRI and optical imaging systems (e.g., BioSpec, Albira, SkyScan); directly competes with MILabs in the preclinical molecular imaging market across similar modalities and customers.

TypeDirect peer
Description

Mediso manufactures preclinical SPECT, PET, CT, and optical imaging systems (nanoScan, MultiScan), directly competing with MILabs for academic and pharma research customers in the small-animal imaging space.

TypeBroad incumbent
Description

Revvity (formerly PerkinElmer Life Sciences) sells IVIS optical, FMT, and broader preclinical imaging solutions as part of a larger life sciences portfolio; competes with MILabs for animal research lab budgets in pharma and academia.

TypeEmerging player
Description

Molecubes is a Belgian emerging player offering preclinical PET, SPECT, CT and optical systems (e.g., β-CUBE, γ-CUBE), targeting similar academic and translational research customers with compact benchtop configurations.

TypeDirect peer
Description

MR Solutions specializes in preclinical cryogen-free MRI systems and multi-modality platforms, with overlapping applications to MILabs' integrated PET-SPECT-CT-MRI preclinical offerings for biomedical research customers.

TypeEmerging player
Description

Aspect Imaging develops preclinical MRI systems and multi-modality platforms; competes with MILabs for translational imaging customers and recently expanded into integrated preclinical imaging workflows.

TypeBroad incumbent
Description

Sedecal manufactures preclinical and clinical imaging hardware including SPECT and CT, with overlapping OEM-style imaging components used in small-animal research; part of a broader medical imaging portfolio.

TypeDirect peer
Description

Trifoil Imaging (previously Gamma Medica) offers preclinical SPECT, PET and CT platforms (e.g., Triumph), directly competing with MILabs in the nuclear imaging preclinical research segment.

TypeEmerging player
Description

Cubresa develops preclinical PET imaging inserts and portable PET systems for brain and translational research; an emerging niche player with overlapping translational imaging applications to MILabs' PET/SPECT preclinical offerings.

TypeBroad incumbent
Description

GE Healthcare is a broad incumbent in medical imaging with product adjacencies in clinical SPECT/PET/CT; while primarily clinical, its portfolio and scale shape the procurement reference frame for translational imaging customers evaluating MILabs systems.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers14 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MILabs

Preclinical Molecular Imaging Systemsmilabs.com

MILabs B.V. designs and sells ultra-high-resolution preclinical and clinical molecular imaging systems (SPECT, PET, CT, Optical) based on proprietary multi-pinhole collimator technology, serving academic research institutions, pharmaceutical companies, and nuclear medicine departments worldwide as a subsidiary of Rigaku Group.

What MILabs does

MILabs B.V., headquartered in Houten, Netherlands, is a privately held developer and manufacturer of ultra-high resolution preclinical and clinical molecular imaging systems. Founded in 2006 as a spin-off from the University Medical Centre Utrecht by Professor Frederik Beekman, the company designs integrated platforms combining SPECT, PET, CT, and Optical imaging modalities on a single scalable workflow. Its core proprietary technologies include clustered multi-pinhole collimators optimized for up to 511 keV photon energies, the VECTor platform (the world's first true simultaneous in vivo SPECT and PET system with sub-millimeter resolution), Confocal/Spectral PET for multi-isotope imaging, and the Super Cluster Collimator for theranostic radionuclides such as Ac-225 and At-211. MILabs also offers the G-SPECT clinical system for human imaging, extending its technology base into diagnostic clinical applications.

The company sells high-value capital equipment primarily to academic research institutions (e.g., Beckman Institute, Mayo Clinic, Duke, Purdue, UPENN, VUB) and pharmaceutical/biotechnology firms, with secondary demand from nuclear medicine departments and CROs. Revenue is generated through hardware sales, system upgrades and accessories, professional service and support contracts, and licensing of patented imaging technologies, all conducted via a quote-based sales process. Distribution combines direct enterprise sales with regional channel partners (e.g., HongKong Meilin Group in China, Mid-Atlantic Imaging Services in the Americas) and co-development relationships (TU Delft, SkyScan, UPENN, RS2D). Since August 2021, MILabs has operated as a subsidiary of Rigaku Group (Tokyo, Japan), continuing to develop advanced preclinical imaging systems under founder-led scientific leadership.

MILabs firmographics

Firmographics
Name
MILabs
Legal name
MILabs B.V.
Website
https://milabs.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
51–100 employees
Short description
MILabs B.V. designs and sells ultra-high-resolution preclinical and clinical molecular imaging systems (SPECT, PET, CT, Optical) based on proprietary multi-pinhole collimator technology, serving academic research institutions, pharmaceutical companies, and nuclear medicine departments worldwide as a subsidiary of Rigaku Group.
Ownership category
akta.pro rank

MILabs industry classification

Industry
Product category
Preclinical Molecular Imaging Systems
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Laboratory Analytical Instruments (3826), Electromedical & Electrotherapeutic Apparatus (3845), X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)
akta.pro industry
PRIMARYHLAHABAE
Nuclear Medicine & Molecular Imaging (SPECT/PET)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)

Keywords

  • Preclinical imaging
  • Molecular imaging systems
  • SPECT imaging
  • PET imaging
  • Micro-CT imaging

Where MILabs is headquartered

Location

Headquarters

HQ city
Houten
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

MILabs business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Preclinical Imaging Systems Sales: MILabs generates primary revenue from selling high-end preclinical molecular imaging systems (SPECT, PET, CT, Optical) to research institutions and pharmaceutical companies. Systems are sold as integrated platforms with various modality configurations.
  2. System Upgrades and Accessories: Revenue from upgrading existing systems with new collimators (e.g., VECTor upgrade for U-SPECT-II), accessories, and application-specific configurations.
  3. Service and Support: Installation, training, application support, and ongoing service maintenance for installed systems through direct staff and regional service partners.
  4. Technology Licensing: Licensing of proprietary imaging technologies and patented collimator designs.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom-configured preclinical imaging systems

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

MILabs product offering

Product offering

Core offering

MILabs designs, manufactures, and sells high-end preclinical and clinical molecular imaging systems for biomedical research. Its portfolio integrates SPECT, PET, CT, and Optical modalities on a single scalable platform, using patented multi-pinhole collimator technology to deliver sub-half-millimeter spatial resolution. Core offerings include U-SPECT, VECTor (simultaneous SPECT/PET), U-PET/CT, Optical imaging, integrated micro-CT, and the G-SPECT clinical system, with specialized collimators such as the Super Cluster Collimator for theranostic radionuclides.

Product overview

MILabs is a preclinical and clinical molecular imaging company offering a comprehensive portfolio of imaging systems. The core product line includes U-SPECT (ultra-high resolution SPECT), VECTor (simultaneous SPECT/PET), U-PET (high-resolution PET with Spectral PET capability), and integrated CT systems. Products range from bench-top mini systems to fully integrated multi-modality platforms combining SPECT/PET/CT and MRI. The portfolio includes specialized collimators (Super Cluster Collimator for theranostics), and extends into clinical imaging with G-SPECT for human SPECT applications. MILabs was acquired by Rigaku Group in August 2021 and continues to develop advanced imaging technologies.

Differentiator

Problem solved

Functional benefit

Products and services

  • VECTor/CT Versatile Emission Computed Tomography system combining simultaneous SPECT and PET imaging with integrated CT for preclinical research; the world's first true simultaneous in vivo SPECT/PET preclinical imaging device delivering sub-mm resolution for both modalities.
  • U-SPECT Ultra-high resolution Single Photon Emission Computed Tomographer providing the highest resolution SPECT imaging available (down to 0.25mm isotropic uniformly over the field of view) with patented focused multi-pinhole cylindrical collimators for preclinical research.
  • U-SPECT/CT Integrated U-SPECT system combined with high-throughput, low-dose micro-CT for fusion of anatomical images with functional SPECT, ensuring high precision data analysis in preclinical research.
  • U-CT High-resolution micro-CT subsystem for anatomical imaging, available at multiple resolution levels with fast scan times and low-dose performance for molecular imaging applications.
  • Optical Imaging Optical imaging module including 3D and 4D capabilities for molecular imaging applications. Available as standalone 2D optical imaging or hybrid Optical/CT imaging system with Duet Optical docking station.
  • VECTor OI/CT Hybrid Optical Imaging with in-line X-ray CT system featuring unique Duet Optical docking station for both high-throughput 2D optical imaging and CT-guided 3D optical tomography of deep tissue.
  • U-PET/CT High-resolution PET system with Confocal PET technology enabling Spectral PET (Color PET) for simultaneous detection of dual isotopes and significantly improved signal-to-noise contrast in preclinical research.
  • Super Cluster Collimator (SC) Accessory transforming challenging theranostic radionuclides into quantifiable preclinical insight. Provides ultra-high sensitivity (~17%) while maintaining spatial resolution of approximately 1.1-1.3mm at high gamma energies, enabling simultaneous multi-photopeak detection for Ac-225, At-211 and other low-signal isotopes.
  • G-SPECT Clinical SPECT System Clinical SPECT system for human use providing <3mm spatial resolution (compared to typical 8-10mm of existing clinical SPECT) with ultra-fast scanning and no rotating detectors. Designed for brain, kidneys and joint imaging with applications in epilepsy, Parkinson's, and Alzheimer's diagnosis.
  • VECTor4 and U-SPECT4 Series New 4-series product line comprising U-SPECT4, U-SPECT4CT, VECTor4 and VECTor4CT with significant improvements including more compact design, dramatically improved X-Ray CT subsystem with reduced radiation dose, increased resolution and speed.
  • PET-SPECT-CT-MRI Platform Comprehensive preclinical imaging platform combining PET, SPECT, CT and MRI modalities. Integrates sub-half-mm SPECT resolution, sub-mm PET resolution, with high-resolution X-ray CT and/or compact cryogen-free 1.5T MRI unit for nanobody and multimodal research.

Quantifiable outcome

  • 0.25mm spatial resolution achieved with U-SPECT technology
  • +4 more outcomes

Companies that use MILabs

Customer profile

Named customers14 records

Segments4 records

Ideal customer profiles4 records

MILabs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature7 records

MILabs partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • HongKong Meilin Group Co., Ltd.coreChannel Partner/ Reseller/ Distributor · 27 January 2015Local partner in China providing sales, technical, and marketing support for MILabs products in the Chinese market. HongKong Meilin Group is a professional distributor for biological research equipment covering molecular imaging, molecular biology, cytology, and immunology.
  • University of PennsylvaniaminorStrategic or Co-development Partner · 1 September 2014Collaboration between UPENN Physics and Instrumentation Group, MILabs, and TU Delft for adaptive SPECT development. Dr. Scott Metzler's work focuses on high performance SPECT instrumentation and image reconstruction.
  • Trace'nTreat Network (Marie Curie ITN)minorStrategic or Co-development Partner · 23 October 2012MILabs participates in Trace'nTreat network, a Marie Curie Initial Training Network funded with over 2 million euros by the European Commission. Network trains young researchers in nuclear diagnostics and radionuclide therapy across academic and private partners including Erasmus MC, TU Delft, and others.
  • SkyScan N.V.coreTechnology or Integration · 11 January 2011Strategic partnership with SkyScan N.V. (Kontich, Belgium) to deliver highest resolution CT systems integrated with MILabs U-SPECT and VECTor platforms. Partnership includes compatible animal holders, bed designs, and Click-Over interface software for automatic fusion of CT datasets with functional molecular imaging.
  • Mid-Atlantic Imaging ServicescoreImplementation/ SI/ Consulting Partner · 9 December 2010Strategic service and support agreement for US and Canada. Mid-Atlantic Imaging Services provides installation and first response service support to MILabs customers, supporting MILabs growth and expansion in the Americas market.
  • TU Delft (Delft University of Technology)coreStrategic or Co-development Partner · 31 May 2009Academic partnership with TU Delft for development of combined PET/SPECT imaging technology leading to VECTor product. Prof. Freek Beekman, founder of MILabs, is professor at TU Delft and previously led development of U-SPECT at the university. Joint research collaboration continues for SPECT protocol optimization and technology development.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

MILabs competitors and assessment

Company assessment

Direct peers

  • Bruker: Bruker's Molecular Imaging business offers preclinical PET, SPECT, CT, MRI and optical imaging systems (e.g., BioSpec, Albira, SkyScan); directly competes with MILabs in the preclinical molecular imaging market across similar modalities and customers.
  • Mediso Medical Imaging Systems: Mediso manufactures preclinical SPECT, PET, CT, and optical imaging systems (nanoScan, MultiScan), directly competing with MILabs for academic and pharma research customers in the small-animal imaging space.
  • MR Solutions: MR Solutions specializes in preclinical cryogen-free MRI systems and multi-modality platforms, with overlapping applications to MILabs' integrated PET-SPECT-CT-MRI preclinical offerings for biomedical research customers.
  • Trifoil Imaging: Trifoil Imaging (previously Gamma Medica) offers preclinical SPECT, PET and CT platforms (e.g., Triumph), directly competing with MILabs in the nuclear imaging preclinical research segment.

Broad incumbents

  • Revvity: Revvity (formerly PerkinElmer Life Sciences) sells IVIS optical, FMT, and broader preclinical imaging solutions as part of a larger life sciences portfolio; competes with MILabs for animal research lab budgets in pharma and academia.
  • Sedecal: Sedecal manufactures preclinical and clinical imaging hardware including SPECT and CT, with overlapping OEM-style imaging components used in small-animal research; part of a broader medical imaging portfolio.
  • GE Healthcare: GE Healthcare is a broad incumbent in medical imaging with product adjacencies in clinical SPECT/PET/CT; while primarily clinical, its portfolio and scale shape the procurement reference frame for translational imaging customers evaluating MILabs systems.

Emerging players

  • Molecubes: Molecubes is a Belgian emerging player offering preclinical PET, SPECT, CT and optical systems (e.g., β-CUBE, γ-CUBE), targeting similar academic and translational research customers with compact benchtop configurations.
  • Aspect Imaging: Aspect Imaging develops preclinical MRI systems and multi-modality platforms; competes with MILabs for translational imaging customers and recently expanded into integrated preclinical imaging workflows.
  • Cubresa: Cubresa develops preclinical PET imaging inserts and portable PET systems for brain and translational research; an emerging niche player with overlapping translational imaging applications to MILabs' PET/SPECT preclinical offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

MILabs social profiles

Digital presence

MILabs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MILabs leadership team

Management profile

Number of profiles

Profiles3 records

MILabs funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MILabs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MILabs

What does MILabs do?

MILabs designs, manufactures, and sells high-end preclinical and clinical molecular imaging systems for biomedical research. Its portfolio integrates SPECT, PET, CT, and Optical modalities on a single scalable platform, using patented multi-pinhole collimator technology to deliver sub-half-millimeter spatial resolution. Core offerings include U-SPECT, VECTor (simultaneous SPECT/PET), U-PET/CT, Optical imaging, integrated micro-CT, and the G-SPECT clinical system, with specialized collimators such as the Super Cluster Collimator for theranostic radionuclides.

Is MILabs a public or private company?

MILabs is a private company. It is classified as corporate owned and is currently operating.

When was MILabs founded?

MILabs was founded in 2006. It employs 51 to 100 people.

Where is MILabs based?

MILabs is headquartered in Houten, Netherlands, in the Europe region.

How does MILabs make money?

Four revenue lines are on record. Preclinical Imaging Systems Sales are the primary driver. The others are system Upgrades and Accessories, service and Support and technology Licensing.

Who are MILabs's main competitors?

Direct peers on record are Bruker, Mediso Medical Imaging Systems, MR Solutions and Trifoil Imaging. Broad incumbents are Revvity, Sedecal and GE Healthcare. Emerging players are Molecubes, Aspect Imaging and Cubresa.

Does MILabs have an API?

No public API is recorded for MILabs.

What industry is MILabs in?

MILabs's product category is Preclinical Molecular Imaging Systems. Its primary akta.pro industry code is HLAHABAE, Nuclear Medicine & Molecular Imaging (SPECT/PET), with a secondary code of HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSmall Animal Imaging (In-Vivo) Global Market Report 2022: Ukraine-Russia War ImpactThe global small animal imaging (in-vivo) market is expected to grow from $2.06 billion in 2021 to $2.27 billion in 2022, and reach $3.38 billion by 2026, driven by increasing healthcare expenditure and technological advancements. The Russia-Ukraine war has disrupted global economic recovery and caused supply chain disruptions affecting this market and many others globally. Key developments include PerkinElmer's April 2022 launch of the Vega automated ultrasound imaging system and Rigaku Corporation's August 2021 acquisition of Netherlands-based MILabs B.V. to expand its preclinical molecular imaging capabilities.LocapesRigaku acquires life science imaging equipment manufacturer MILabs – Locapes Investment FundRigaku Corporation has acquired all issued shares of MILabs B.V. on August 2, 2021, marking its entry into the life sciences business. This acquisition will enable Rigaku to expand its global life sciences modality business by integrating MILabs' multi-modality imaging technologies with its own X-ray imaging systems for animals.PR NewswireGlobal Medical Imaging Market Report 2021-2026 Featuring Siemens Healthineers, GE, Philips, Canon Medical Systems, Fujifilm SonoSite, Carestream Health, Hologic, Mediso, MILabs, MR SolutionsResearchAndMarkets.com published a market research report on the Global Medical Imaging Market (2021-2026), valued at USD 39.94 billion in 2020, covering products including X-Ray, Ultrasound, MRI, CT Scan, and Nuclear Imaging across hospitals, diagnostic imaging centers, and ambulatory imaging centers. The report identifies technological advancements, increasing chronic disease prevalence, and growing government emphasis on early diagnosis as key market drivers, with North America holding a major market share. The competitive landscape analysis profiles major players including Siemens Healthineers, General Electric, Philips, Canon Medical Systems Corporation, Fujifilm SonoSite, Carestream Health, Hologic, Mediso, MILabs, and MR Solutions.BioWorldLexagene Miqlab detects U.K. and South African variantsLexagene Holdings Inc. configured its Miqlab point-of-care system to detect U.K. and South African SARS-CoV-2 variants, screening for multiple respiratory pathogens. The company began studies to support its U.S. FDA emergency use authorization filing in late December 2020, which would make it the first open-access POC device to gain an EUA.News-MedicalTAU's new Translational Medical Research Center acquires MILabs' VECTor PETTel Aviv University's Translational Medical Research Center acquired MILabs' VECTor PET/SPECT/CT system for its Sackler Cellular and Molecular Imaging Center. The multimodal imaging system aims to accelerate bench discoveries into clinical trials by enabling simultaneous tracer imaging. The acquisition is expected to strengthen the Israeli drug industry.News-MedicalCUIMC selects MILabs for upgrades to its molecular imaging capabilitiesColumbia University Irving Medical Center's Department of Radiology acquired the MILabs VECTor system to upgrade its molecular imaging capabilities. The multimodal platform integrates PET, SPECT, optical, and CT imaging, and was awarded Commercial Innovation of the Year 2018. The system will support the PET Center and the Irving Institute for Clinical and Translational Research.News-MedicalMILabs installs pre-clinical Adaptive microCT scanner at Jagiellonian University in PolandJagiellonian University in Kraków installed MILabs' Adaptive U-CT, becoming Poland's first institute to use it for in-vivo preclinical imaging. The system adapts to researchers' applications, covering bones, ossicles, and soft tissues in mice and larger rodents. The university's microbiology department selected it for its versatile, radiation-efficient design.News-MedicalMILabs' new Broadband Photon Tomography selected for Innovation of the Year awardMILabs' Broadband Photon Tomography technique was nominated for the World Molecular Imaging Society's Innovation of the Year 2018 award. The technique, implemented on the VECTor6 platform, enables simultaneous nuclear and optical imaging with high-resolution PET and SPECT, and 3D optical images from single acquisitions.News-MedicalMILabs completes installation of new X-ray CT system at University of SydneyMILabs completed installation of its Adaptive U-CTXUHR X-ray CT system at Sydney Imaging, a University of Sydney research facility. The system offers low-dose, fast, high-resolution imaging for animal models and can be upgraded to molecular CT. MILabs expects to adapt it for molecular imaging if needed.News-MedicalMILabs' ultra-high resolution U-CT system installed at The Hebrew University of JerusalemMILabs installed an ultra-high resolution U-CT system at The Hebrew University of Jerusalem, where Professor Galia Blum's lab uses it for drug discovery. The system will accelerate research on cancer, atherosclerosis, arthritis, and autoimmune diseases using gold- or iodine-labeled probes.